SciSparc Ltd. (SPRC) 股票分析

公司概述

SciSparc Ltd. operates as a clinical-stage pharmaceutical entity dedicated to developing therapeutic interventions based on cannabinoid therapies, targeting a range of neurological and psychiatric conditions. The company functions within the Healthcare sector, specifically the Biotechnology industry, a classification that signifies its focus on innovation-driven R&D rather than established commercial production. SciSparc Ltd. currently maintains a market capitalization of $1.93 million and reports trailing twelve-month revenue of $1.31 million, while employing only two staff members. These valuation and revenue figures indicate that the company operates at a very early-stage scale, reflecting a business model heavily reliant on future drug approval milestones and clinical trial outcomes rather than current cash flow generation. The minimal workforce relative to the biotechnology sector norms suggests a lean operational structure typical of pre-revenue or early-revenue development firms focusing on proprietary asset creation.

财务健康

The company reported trailing twelve-month revenue of $1.31 million alongside a net income loss of $-6,480,000 and an EBITDA of $-7,029,000, revealing a substantial gap between top-line sales and bottom-line profitability that underscores a cost structure dominated by research and development expenditures. Although free cash flow data is not disclosed, the absence of reported figures typically implies significant cash burn associated with clinical trial activities common in clinical-stage development. Gross margin stands at 38.7%, indicating that the company retains a moderate portion of revenue after direct costs of goods sold, while the operating margin of -569.5% and profit margin of 0.0% highlight the severe operational losses incurred during the drug discovery and clinical validation phases. Regarding liquidity and leverage, the company holds $0 in debt, yet specific cash balance figures are unavailable; the lack of debt liability suggests a conservative capital structure despite the negative earnings position. The current ratio is not reported, preventing a direct assessment of short-term liquidity coverage relative to current liabilities. Return on equity is calculated at -1281.5%, and return on assets is not available, metrics that collectively reveal the company has not yet achieved positive equity generation or asset efficiency, reflecting the inherent financial risks of early-stage biotechnology development.

估值评估

The trailing twelve-month P/E ratio is listed as 0.00, while the forward P/E is not available, a disparity that implies the market cannot value the stock based on current earnings due to significant losses and cannot project earnings growth sufficient to generate a meaningful forward multiple. The price-to-book ratio is recorded at 0.02, indicating that the market values the company's equity at a fraction of its book value, which often occurs when intangible assets like drug pipelines are not fully captured on the balance sheet or when future profitability is highly uncertain. Alternative valuation metrics such as the price-to-sales ratio of 1.48 and the unavailable EV/EBITDA provide a different perspective, suggesting investors are pricing the stock based on revenue potential rather than profitability. The 52-week price range spans from a low of $3.32 to a high of $94.50, and without the specific current share price, the precise trading position relative to this wide volatility band cannot be numerically calculated, though the range demonstrates extreme price dispersion typical of small-cap biotech firms. The stock exhibits a beta of 1.33, signifying that the share price is expected to be approximately 33% more volatile than the broader market, reflecting the heightened risk profile associated with speculative biotechnology investments.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both marked as not available, meaning historical growth trajectories cannot be established to determine if earnings are growing faster or slower than revenue. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that SciSparc Ltd. does not distribute cash to shareholders but instead retains all resources to fund ongoing clinical programs and operational expenses. Consequently, the company's strategy focuses entirely on reinvesting earnings into research and development rather than providing income to investors, a standard approach for clinical-stage firms seeking to extend their product pipeline. The overall growth and income profile is characterized by a lack of historical growth data and an absence of dividend income, positioning the asset purely as a speculative vehicle for potential future commercialization of cannabinoid-based therapies.